All Updates

All Updates

icon
Filter
Product updates
Myriad Genetics obtains second patent for tumor-informed MRD assay technology
Precision Medicine
Jul 9, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jul 9, 2024

Myriad Genetics obtains second patent for tumor-informed MRD assay technology

Product updates

  • Myriad Genetics has received a second patent from the US Patent and Trademark Office for its molecular residual disease (MRD) assay, Precise MRD, which detects circulating tumor DNA in patient fluid samples.

  • The assay is claimed to track thousands of tumor-specific variants identified through genome-scale sequencing, enabling it to detect tumor DNA at lower levels than currently available products. 

  • Analyst QuickTake: Myriad collaborated with the University of Texas MD Anderson Cancer Center in June 2023 and Memorial Sloan Kettering Cancer Center (MSK) in September 2023 to test the potential of its MRD testing platform as a non-invasive tool for treatment selection, monitoring disease progression, and tracking treatment response in cancer patients. The first patent for the MRD assay was granted in March 2024

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.